Kurum Yazarı "Mutlu, Yaşa Gül" İçin Listeleme
-
Clinical characteristics and outcomes of COVID-19 in Turkish patients with hematological malignancies
Civriz Bozdağ, Sinem; Cengiz Seval, Güldane; Yönal Hindilerden, İpek; Hindilerden, Fehmi; Andıç, Neslihan; Baydar, Mustafa; Aydın Kanyar, Lale; Toprak, Selami Koçak; Göksoy, Hasan Sami; Balık Aydın, Berrin; Demirci, Ufuk; Can, Ferda; Özkocaman, Vildan; Gündüz, Eren; Güven, Zeynep Tuğba; Özkurt, Zübeyde Nur; Demircioğlu, Sinan; Beksaç, Meral; İnce, İdris; Yılmaz, Umut; Eroğlu Küçükdiler, Hilal; Abishov, Elgün; Yavuz, Boran; Ataş, Ünal; Mutlu, Yaşa Gül; Baş, Volkan; Özkalemkaş, Fahir; Üsküdar Teke, Hava; Gürsoy, Vildan; Çelik, Serhat; Çiftçiler, Rafiye; Yağcı, Münci; Topçuoğlu, Pervin; Çeneli, Özcan; Abbasov, Hamza; Selim, Cem; Ar, Muhlis Cem; Yücel, Orhan Kemal; Sadri, Sevil; Albayrak, Canan; Demir, Ahmet Muzaffer; Güler, Nil; Keklik, Muzaffer; Terzi, Hatice; Doğan, Ali; Yegin, Zeynep Arzu; Kurt Yüksel, Meltem; Sadri, Soğol; Yavaşoğlu, İrfan; Beköz, Hüseyin Saffet; Aksu, Tekin; Maral, Senem; Erol, Veysel; Kaynar, Leylagül; İlhan, Osman; Bolaman, Ali Zahit; Sevindik, Ömür Gökmen; Akyay, Arzu; Özcan, Muhit; Gürman, Günhan; Ünal, Şule; Yavuz, Yasemin; Diz Küçükkaya, Reyhan; Özsan, Güner Hayri (NLM (Medline), 2022)Objective: Patients with solid malignancies are more vulnerable to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection than the healthy population. The outcome of SARS-CoV-2 infection in highly ... -
First-line usage of daratumumab, lenalidomide, dexamethasone (DRd) combination in a case of castleman disease variant of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (CD-POEMS)
Sevindik, Ömür Gökmen; Mutlu, Yaşa Gül; Balık Aydın, Berrin; Serin, İstemi (Lippincot Williams & Wilkins, 2022)Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (POEMS) is a rare paraneoplastic syndrome of an underlying plasma cell disorder (PCD).1 Castleman disease (CD), itself, can ... -
Mutation profile of the patients diagnosed with myeloid neoplasia tested with next generation sequencing and clinical implications
Mutlu, Yaşa Gül; Balık Aydın, Berrin; Ayaz, Akif; Seca, Fatma; Sevindik, Ömür Gökmen (Inonu University Faculty of Medicine, 2022)Aim: To analyze the distribution of gene mutations in myeloid neoplasias, based on next generating sequencing technology (NGS) and evaluate their clinical implications and impact on the risk stratification. Materials and ... -
Pegaspargase, venetoclax, and nelarabine: A successful bridge to allogeneic hematopoietic stem cell transplantation in a relapsed/refractory T-cell acute lymphoblastic leukemia patient
Yiğit Kaya, Süreyya; Bektaş, Şebnem; Aşkın, Abdullah Emre; Balık Aydın, Berrin; Mutlu, Yaşa Gül; Sevindik, Ömür Gökmen (Springer, 2023)... -
Plerixafor in autologous stem cell transplantation: Does it affect engraftment kinetics?
Serin, İstemi; Sevindik, Ömür Gökmen; Balık Aydın, Berrin; Melek, Elif; Mutlu, Yaşa Gül; Bilgen, Hülya; Beköz, Hüseyin; Kaynar, Leylagül (Elsevier Ltd, 2023)Plerixafor increases stem cell mobilization by reversibly binding to the chemokine receptor CXCR4. In our study, we examined the results of mobilization with plerixafor and granulocyte colony-stimulating factor (G-CSF) and ... -
Predicting the CD34 content of mobilized peripheral blood leukapheresis products: Single institution experience over 20 years
Mutlu, Yaşa Gül; Sevcik, Joan; Kiss, Joseph Elmer; Lister, John; Moore, Linda R.; Donnenberg, Albert D. (Elsevier Science Ltd, 2024)Background aims: Since the standardization of CD34 measurement by flow cytometry, predictors of leukapheresis CD34 yield have played a pivotal role in planning donor leukaphereses. We describe here a single institution's ... -
Prognostic factors and intensive care outcome in post-transplant phase of hematopoietic stem cell transplantation intensive care outcome in hematopoietic stem cell transplantation
Mutlu, Yaşa Gül; Balık Aydın, Berrin; Erdoğan, Cem; Kızılaslan, Deniz; Beköz, Hüseyin Saffet; Gemici, Aliihsan; Kaynar, Leylagül; Sevindik, Ömür Gökmen (Springer India, 2023)Introduction To identify new clinical and biologic parameters associated with short-term survival in allogeneic or autologous hematopoietic stem cell transplantation (HSCT) patients who were admitted to the intensive care ... -
Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: First reported case
Mutlu, Yaşa Gül; Yiğit Kaya, Süreyya; Maral, Senem; Melek, Elif; Başlar, Zafer; Kaynar, Leylagül; Sevindik, Ömür Gökmen (Frontiers Media SA, 2023)Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication associated with poor prognosis and limited treatment options. Emerging T-cell directing therapies, such as bispecific ... -
Should core needle lymph node biopsy be a relevant alternative to surgical excisional biopsy in diagnostic work up of lymphomas?
Mutlu, Yaşa Gül; Balık Aydın, Berrin; Çakır, Aslı; Canöz, Özlem; Erol, Cengiz; Sevindik, Ömür Gökmen (AVES, 2023)Objective: Surgical excisional biopsy is accepted as the standard of care approach in the diagnosis of lymphomas. Financial issues related to the increased cost and the invasive nature of the procedure forced physicians ... -
Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience
Yiğit Kaya, Süreyya; Mutlu, Yaşa Gül; Malkan, Ümit Yavuz; Mehtap, Özgür; Keklik Karadağ, Fatma; Korkmaz, Gülten; Elverdi, Tuğrul; Saydam, Güray; Özet, Gülsüm; Ar, Muhlis Cem; Melek, Elif; Maral, Senem; Kaynar, Leylagül; Sevindik, Ömür Gökmen (2024)Background: Hairy cell leukemia (HCL) is a rare mature B-cell malignancy that is primarily treated with purine analogues. However, relapse remains a significant challenge, prompting the search for alternative therapies. ... -
To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission
Sevindik, Ömür Gökmen; Mergen, Mahmut; Mergen, Sena; Mutlu, Yaşa Gül; Balık Aydın, Berrin; Serin, İstemi (Springer Science and Business Media Deutschland GmbH, 2022)Dear Editor, Acute myeloid leukemia is the most common sub-type of acute leukemia in adulthood [1]. It has a detrimental prognosis with conventional combination chemotherapy, mainly with anthracyclines and cytarabine. ...